Active, not recruitingPhase 2NCT05036434

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Studying Adrenocortical carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Center, Korea
Principal Investigator
Tak Yun
National Cancer Center, Republic of Korea
Intervention
Pembrolizumab / Lenvatinib(drug)
Enrollment
30 enrolled
Eligibility
19 years · All sexes
Timeline
20212027

Study locations (1)

Collaborators

MSD Korea Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05036434 on ClinicalTrials.gov

Other trials for Adrenocortical carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adrenocortical carcinoma

← Back to all trials